Market news

Detailed price information for Neumora Therapeutics Inc (NMRA-Q) from The Globe and Mail including charting and trades.

Detailed price information for Neumora Therapeutics Inc (NMRA-Q) from The Globe and Mail including charting and trades.

Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer’s disease (AD) agitation and NMRA-898 in schizophrenia with clinical data expected in fourth quarter of 2026 and second half of 2026, respectively Joshua Pinto, Ph.D., appointed chief executive officer and member of the Board of Directors Paul L. Berns appointed Executive Chair, continuing to serve as a key strategic leade

Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today reported favorable pre-clinical toxicology results from NMRA-215, a potentially best-in-class, highly b

Neumora Therapeutics is back in focus after analysts cut their fair value estimate from US$8.91 to US$6.53 per share, a reduction of about 27% that resets expectations around the stock. Much of this shift tracks recent commentary on the decision to discontinue navacaprant, remove associated costs, and place more weight on the earlier stage pipeline, which bullish and bearish voices interpret very differently. As you read on, you will see how these updated targets fit into the evolving...